POSIFLEX
16.1.2023 05:26:36 CET | Business Wire | Press release
As one of the world’s top five electronic Point of Sale (POS) system suppliers, Posiflex Technology is wrapping up a particularly banner year for 2022, benefiting from vigorous refurbishments in retail and hospitality industries during the post COVID-19 pandemic era. With excellent supply chain management and risk control, Posiflex has been less affected by the global supply crisis resulted from COVID-19 lockdowns and geographical conflicts on top of other risk factors during 2022, and the company is eyeing toward a further leap in its global-leading position.
World’s 5th Ranked POS Supplier Rises to the Challenge
According to the latest survey conducted by market intelligence firm RBR, Posiflex ranks as the 5th biggest POS brand in terms of shipped units throughout 2021, with its strongest presence in Southeast Asia, the Middle East, Africa and Europe. The RBR survey also found that Posiflex rose to 1st place in countries like India, the Philippines, Saudi Arabia and Greece, with its market share in India as high as 54%, and Saudi Arabia 42%.
Why Customers Choose Posiflex: Customization Capability, Quality and Delivery
A new customer feedback analysis conducted by RBR has revealed that Posiflex customers on a worldwide base are most satisfied with the company’s professional support including customization service, reliable quality, and stable delivery (effective and efficient logistics), ranking as the top 3 Posiflex advantages in the eyes of customers.
- Customization Service and better technical support
Posiflex is the only company among the top 5 POS suppliers to adopt a vertical integration strategy— it designs, manufactures, and sells POS systems and peripherals in-house, which means it is able to provide one-stop shopping service to customers as well as small volume customization to fit specific requirements of customers from different countries with various application scenarios and needs, including OS options, logo co-branding and special peripheral specs.
As Posiflex designs and manufactures products on its own, it is well-versed in technical details of its products and can be quicker and more helpful in responding to customers’ needs.
- Reliable quality
To provide reliable products, Posiflex takes care in selecting quality materials and conducts comprehensive tests before shipment, including vibration test, drop test, plus the industry’s highest standard full-system loading test in 40°C burn-in chamber for 12+ hours for all shipping products. Customers’ feedback also shows high satisfaction with Posiflex’s product quality.
- Good command of supply chain logistics
By merging various stages of production and supply chain into its own operations, Posiflex has also achieved better command of supply chain logistics with reduced need for outside entities. This, combined with a well-managed supplier network, has accumulated into better supply resilience for Posiflex to achieve more stable product deliveries and shorter delivery times than its competitors during the global supply shortage crisis in the past two years of the pandemic.
“Your success is our vision,” said Owen Chen, CEO of Posiflex, citing the company’s core values slogan. “We combine our technological advantages with customer needs and provide the most feasible products and services for partners and end users,” said Chen.
About POSIFLEX Group
Posiflex Group is a global leading Commercial Internet of Things (CIoT) enabler dedicated to providing O2O and embedded solutions. The group now is pillared by three business entities—Posiflex Technology, Portwell Inc. and US-based KIOSK Information Systems (KIS), specialized in the manufacturing of POS, embedded IPC and self-service kiosk respectively, with a common goal in pursuing a brave new world of smart commerce, where transactions become faster and more convenient physically or digitally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom